Open access · CC-BY
via OpenAlex
mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy
European Journal of Immunology · 2021 · ▲ 19 citations
Deregulated nutrient-sensing
Altered intercellular communication
Rapamycin / mTOR inhibition
Human
Review
Abstract
Immune cells are important constituents of the tumor microenvironment and essential in eradicating tumor cells during conventional therapies or novel immunotherapies. The mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) signaling pathway senses the intra- and extracellular nutrient status, growth factor supply, and cell stress-related changes to coordinate cellular metabolism and activation dictating effector and memory functions in mainly all hematopoietic immune cells. In addition, the mTOR complex 1 (mTORC1) and mTORC2 are frequently deregulated and become activated in cancer cells to drive cell transformation, survival, neovascularization, and invasion. In this review, we provide an overview of the influence of mTOR complexes on immune and cancer cell function and metabolism. We discuss how mTOR inhibitors aiming to target cancer cells will influence immunometabolic cell functions participating either in antitumor responses or favoring tumor cell progression in individual immune cells. We suggest immunometabolism as the weak spot of anticancer therapy and propose to evaluate patients according to their predominant immune cell subtype in the cancer tissue. Advances in metabolic drug development that hold promise for more effective treatments in different types of cancer will have to consider their effects on the immune system.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/eji.202149270
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Braun, C., & Weichhart, T. (2021). mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy. <em>European Journal of Immunology</em>. https://doi.org/10.1002/eji.202149270
Vancouver
Braun C, Weichhart T. mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy. European Journal of Immunology. 2021. doi:10.1002/eji.202149270.
BibTeX
@article{c2021mTORde,
title = {mTOR‐dependent immunometabolism as Achilles' heel of anticancer therapy},
author = {C Braun and Thomas Weichhart},
journal = {European Journal of Immunology},
year = {2021},
doi = {10.1002/eji.202149270},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cells 2019
Open access · CC-BY
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
The Journal of Immunology 2014
Open access · OA
Mechanistic Target of Rapamycin Inhibition Extends Cellular Lifespan in Dendritic Cells by Preserving Mitochondrial Function
Cold Spring Harbor Perspectives in Biology 2012
Preprint · OA
mTOR-Dependent Cell Survival Mechanisms
Frontiers in Oncology 2020
Open access · CC-BY
How Autophagy Shapes the Tumor Microenvironment in Ovarian Cancer
Frontiers in Immunology 2019
Open access · CC-BY
Regulation of Dendritic Cell Immune Function and Metabolism by Cellular Nutrient Sensor Mammalian Target of Rapamycin (mTOR)
Journal of Hematology & Oncology 2019
Open access · CC-BY